FC2ブログ

バイオの戯言

ライフサイエンスに関する話題についてコメント(戯言?)を述べていくブログです。

【プレスリリースメモ】 RNAi関係 (2013.8.5)  

<Alnylam Pharmaceuticals>
Alnylam to Webcast Conference Call Discussing Second Quarter 2013 Financial Results(2013.8.1)

<Mesoblast>
MSB Receives $4.3M Pipeline Funds from Australian Government(2013.7.18)
Appendix 4C - quarterly(2013.8.1)

<Antisense Pharma>
Antisense Pharma to Present at 13th Annual Biotech in Europe Investor Forum(2013.7.16)

<Antisense Therapeutics>
Appendix 4C Quarterly(2013.7.23)
ATL1103 Phase II Trial Update(2013.8.2)

<Arrowhead Research>
Arrowhead Begins Phase 1 Trial of RNAi Therapeutic ARC-520 for Treatment of Chronic Hepatitis B Infection(2013.7.23)
Arrowhead to Report Fiscal 2013 Third Quarter Financial Results(2013.7.31)

<Benitec>
Benitec commences trading on a consolidated basis (Share price can be seen on ASX code: BLTDA)(2013.7.22)
Benitec raises additional A$2.84 million with Share Purchase Plan(2013.7.31)

<Bio-Path Holdings>
Bio-Path Holdings Initiates Development of Liposomal Grb-2 for Triple Negative and Inflammatory Breast Cancers(2013.7.22)

<Dicerna Pharmaceuticals>
Dicerna Secures $60 Million in Oversubscribed Series C Financing(2013.8.1)

<Dynavax Technologies>
Dynavax Reports Second Quarter 2013 Financial Results(2013.7.29)

<enGene>
Lumira Capital announces investment in enGene, Inc.(2013.8.1)

<Generex Biotechnology>
Generex Confirms Conference Call with Members of the Antigen Express Scientific Advisory Board(2013.7.23)

<Gradalis>
Gradalis Appoints Joseph M. Limber President and Chief Executive Officer(2013.7.23)

<Idera Pharmaceuticals>
Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial(2013.7.18)

<Integrated DNA Technologies>
IDT opens SGD 6 million manufacturing facility in Singapore(2013.7.24)

<InteRNA Technologies B.V.>
InteRNA’s R&D collaboration partner UMC St. Radboud receives grant from Stichting voor de Technische Wetenschappen(2013.7.17)

<Isis Pharmaceuticals>
Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions of ApoC-III and Triglycerides in Patients With High Triglycerides Taking Fibrates(2013.7.22)
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2013 Financial Results Conference Call(2013.7.29)
Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx(2013.7.30)

<Lorus Therapeutics>
Lorus Therapeutics Reports Results for Fiscal Year 2013(2013.7.15)

<Mirna Therapeutics>
Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio(2013.7.30)

<Mirus Bio>
Mirus Announces: TransIT-X2™ Dynamic Delivery System(2013.7.29)

<Moderna Therapeutics>
Paula Soteropoulos has joined Moderna as the Cardiometabolism Business Unit General Manager and Senior Vice President of Strategic Alliances(2013.7.29)
Moderna appoints industry veteran Joe Bolen as President of Research and Development(2013.7.31)

<OncoGenex Technologies>
OncoGenex Announces Completion of Patient Enrollment in the Borealis-1 TM Trial of OGX-427 in Metastatic Bladder Cancer(2013.7.16)
OncoGenex to Webcast Discussion of Clinical Development Program and Second Quarter 2013 Financial Results on August 8, 2013(2013.7.30)
OncoGenex Announces that the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer is Now Open for Enrollment(2013.8.1)

<OPKO Health>
OPKO Health Announces Appointment of David Okrongly, Ph.D. as President of its Diagnostics Business Unit(2013.7.16)
OPKO's Citicoline Products Approved for Commercialization in Spain(2013.7.24)

<Pharmaxis>
Investor Conference Call Details(2013.7.16)
Recording of Investor Briefing(2013.7.18)
Pharmaxis Announces Improved PBS Listing of Bronchitol(2013.7.18)

<Regulus Therapeutics>
Regulus Announces Pricing of Public Offering of Common Stock(2013.7.17)
Regulus Announces Completion of Public Offering and Exercise in Full of Overallotment Option(2013.7.23)

<RXi Pharmaceuticals>
RXi Pharmaceuticals Announces CEO Interview(2013.7.18)
RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split(2013.7.22)

<Sarepta Therapeutics>
Sarepta Therapeutics to Host Conference Call to Discuss Regulatory Update for Eteplirsen on Wednesday, July 24, 2013(2013.7.23)
Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy in First Half of 2014(2013.7.24)
Sarepta Therapeutics to Announce Second Quarter 2013 Financial Results and Corporate Update on August 8, 2013(2013.7.25)
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences(2013.7.30)

<Tekmira Pharmaceuticals>
Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)(2013.7.18)

<Valeant Pharmaceuticals>
Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013(2013.7.15)

<Vical>
Vical Announces News Release and Conference Call Schedule for Second Quarter 2013 Financial Results(2013.7.25)
Vical Reports Second Quarter 2013 Financial Results, Projects Phase 3 Data Release in August and Establishes Quiet Period(2013.8.1)

<アクアセラピューティクス>
・株式会社ドーガン・インベストメンツ(本社:福岡市中央区、代表取締役:森大介)および、三菱UFJキャピタル株式会社(本社:東京都中央区、代表取締役社長:安藤啓)が運営する投資ファンドは、当社に対します総額3千万円の第三者割当増資の実施を決定しましたのでお知らせいたします。
当社は、本年4月1日に実施しました第三者割当増資と併せ、当初の目標であります5億円の増資を完了いたしました。これら増資による資金を活用し、本格的な核酸医薬の開発を進めてまいります(2013.8.1)

<アンジェスMG>
NF-kBデコイオリゴを用いたアトピー性皮膚炎治療薬の第I相臨床試験において皮膚安全性を確認(2013.7.23)
虚血性疾患治療剤「コラテジェン」の小規模臨床試験プロトコールのNIH によるRAC レビューの完了について(2013.7.24)
第24 回新株予約権(第三者割当て)(行使価額修正条項付)の大量行使に関するお知らせ(2013.7.24)
・アンジェスMG とテラが共同研究および開発の基本契約を締結 ―子宮頸がんの前がん病変治療ワクチンプロジェクトについて―(2013.7.30)
第24 回新株予約権(第三者割当て)(行使価額修正条項付)の月間行使状況に関するお知らせ(2013.8.1)
当社提携先であるVical 社のAllovectin第III相臨床試験の進捗状況について ~トップラインデータの公表を8 月に予定~(2013.8.2)

<ジーンケア研究所>
Publication Listを更新(2013.7.4)

<ステリック再生医科学研究所>
・F. Hoffmann-La Roche AGが当社NASH-肝癌モデル(STAM®モデル)マウスを用いた研究成果を 「2013 FASEB※ Summer Research Conference」(開催地:北海道ニセコ町)で発表(2013.8.5)

<日東電工>
「日東電工グループ レポート2013」掲載しました(2013.8.1) ← 核酸医薬開発の記載あり


スポンサーサイト
[ 2013/08/05 10:49 ] プレスリリース | TB(0) | CM(0)
コメントの投稿













管理者にだけ表示を許可する
最新ニュース
お気に入り
カレンダー(月別)
07 ≪│2018/08│≫ 09
- - - 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 -
特選品
特許関係の書籍-3
特許関係の書籍-2
特許関係の書籍-1
情報関係の書籍
月別アーカイブ
プロフィール

のぐひで

Author:のぐひで
FC2ブログへようこそ!